Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases

Neuroscience Letters

Volumn 583, Issue , 2014, Pages 188-193

  Pchelina, S N ^a,b,d   Nuzhnyi, E P ^b   Emelyanov, A K ^a,b,d   Boukina, T M ^c   Usenko, T S ^a,b   Nikolaev, M A ^a,d   Salogub, G N ^b   Yakimovskii, A F ^b   Zakharova, E Yu ^c  

^a PETERSBURG NUCLEAR PHYSICS INSTITUTE   (Russian Federation)

^b PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^c RESEARCH CENTRE FOR MEDICAL GENETICS   (Russian Federation)

^d ST PETERSBURG ACADEMIC UNIVERSITY   (Russian Federation)

Author keywords

Alpha synuclein; Gaucher disease; Lysosomal storage diseases; Oligomerization; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; GLUCOSYLCERAMIDASE; IMIGLUCERASE; OLIGOMERIC ALPHA SYNUCLEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; GENE; GENE MUTATION; GLOBOID CELL LEUKODYSTROPHY; GLUCOSYLCERAMIDASE GENE; HUMAN; LYSOSOME STORAGE DISEASE; MALE; NIEMANN PICK DISEASE; OLIGOMERIZATION; PARKINSON DISEASE; PROTEIN BLOOD LEVEL; WOLMAN DISEASE; AGE; BLOOD; CASE CONTROL STUDY; INFANT; LYSOSOMAL STORAGE DISEASES; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ALPHA-SYNUCLEIN; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; ENZYME REPLACEMENT THERAPY; FEMALE; HUMANS; INFANT; LYSOSOMAL STORAGE DISEASES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84908310492     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.09.041     Document Type: Article

References (26)

1. Argyriou A., Dermentzaki G., Papasilekas T., Moraitou M., Stamboulis E., Vekrellis K., Michelakakis H., Stefanis L. Increased dimerization of alpha-synuclein in erythrocytes in Gaucher disease and aging. Neurosci. Lett. 2012, 528:205-209.
2. Brighina L., Prigione A., Begni B., Galbussera A., Andreoni S., Piolti R., Ferrarese C. Lymphomonocyte alpha-synuclein levels in aging and in Parkinson disease. Neurobiol. Aging 2010, 31:884-885.
3. Bartels T., Choi J.G., Selkoe D.J. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011, 477:107-110.
4. Choi J.H., Stubblefield B., Cookson M.R., Goldin E., Velayati A., Tayebi N., Sidransky E. Aggregation of alpha-synuclein in brain samples from subjects with glucocerebrosidase mutations. Mol. Genet. Metab. 2011, 104:185-188.
5. Cookson M.R., Bandmann O. Parkinson's disease: insight from pathways. Hum. Mol. Genet. 2010, 19:21-27.
6. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
7. Dekker N., van Dussen L., Hollak C.E., Overkleeft H., Scheij S., Ghauharali K., van Breemen M.J., Ferraz M.J., Groener J.E., Maas M., Wijburg F.A., Speijer D., Tylki-Szymanska A., Mistry P.K., Boot R.G., Aerts J.M. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood 2011, 118:118-127.
8. Emelyanov A., Boukina T., Yakimovskii A., Usenko T., Drosdova A., Zakharchuk A., Andoskin P., Dubina M., Schwarzman A., Pchelina S. Glucocerebrosidase gene mutations are associated with Parkinson's disease in Russia. Mov. Disord. 2012, 27:158-159.
9. Fan M., Sidhu R., Fujiwara H., Tortelli B., Zhang J., Davidson C., Walkley S.U., Bagel J.H., Vite C., Yanjanin N.M., Porter F.D., Schaffer J.E., Ory D.S. Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling. J. Lipid Res. 2013, 54:2800-2814.
10. Fjorback A.W., Varming K., Jensen P.H. Determination of alpha-synuclein concentration in human plasma using ELISA. Scand. J. Clin. Lab. Invest. 2007, 67:431-435.
11. Foulds P.G., Mitchell J.D., Parker A., Turner R., Green G., Diggle P., Hasegawa M., Taylor M., Mann D., Allsop D. Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J. 2011, 25:4127-4137.
12. Gan-Or Z., Ozelius L.J., Bar-Shira A., Saunders-Pullman R., Mirelman A., Kornreich R., Gana-Weisz M., Raymond D., Rozenkrantz L., Deik A., Gurevich T., Gross S.J., Schreiber-Agus N., Giladi N., Bressman S.B., Orr-Urtreger A. The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology 2013, 80:1606-1610.
13. Ginns E.I., Mak S.K., Ko N., Karlgren J., Akbarian S., Chou V.P., Guo Y., Lim A., Samuelsson S., LaMarca M.L., Vazquez-DeRose J., Manning-Boğ A.B. Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction. Mol. Genet. Metab. 2014, 111:152-162.
14. Kang S., Heo T.H., Kim S.J. Altered levels of α-synuclein and sphingolipids in Batten disease lymphoblast cells. Gene 2014, 539:181-185.
15. Kim S., Jeon B.S., Heo C., Im P.S., Ahn T.B., Seo J.H., Kim H.S., Park C.H., Choi S.H., Cho S.H., Lee W.J., Suh Y.H. Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson's disease. FASEB J. 2004, 18:1615-1617.
16. Kovacs G.G., Wagner U., Dumont B., Pikkarainen M., Osman A.A., Streichenberger N., Leisser I., Verchère J., Baron T., Alafuzoff I., Budka H., Perret-Liaudet A., Lachmann I. An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology. Acta Neuropathol. 2012, 124:37-50.
17. Mazzulli J.R., Xu Y.H., Sun Y., Knight A.L., McLean P.J., Caldwell G.A., Sidransky E., Grabowski G.A., Krainc D. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146:37-52.
18. McGlinchey R.P., Lee J.C. Emerging insights into the mechanistic link between α-synuclein and glucocerebrosidase in Parkinson's disease. Biochem. Soc. Trans. 2013, 41:1509-1512.
19. Mielke M.M., Maetzler W., Haughey N.J., Bandaru V.V., Savica R., Deuschle C., Gasser T., Hauser A.K., Gräber-Sultan S., Schleicher E., Berg D., Liepelt-Scarfone I. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. PLOS ONE 2013, 8:e73094.
20. Parnetti L., Chiasserini D., Persichetti E., Eusebi P., Varghese S., Qureshi M.M., Dardis A., Deganuto M., De Carlo C., Castrioto A., Balducci C., Paciotti S., Tambasco N., Bembi B., Bonanni L., Onofrj M., Rossi A., Beccari T., El-Agnaf O., Calabresi P. Cerebrospinal fluid lysosomal enzymes and α-synuclein in Parkinson's disease. Mov. Disord. 2014, 29:1019-1027.
21. Sardi S.P., Clarke J., Viel C., Chan M., Tamsett T.J., Treleaven C.M., Bu J., Sweet L., Passini M.A., Dodge J.C., Yu W.H., Sidman R.L., Cheng S.H., Shihabuddin L.S. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:3537-3542.
22. Shi M., Zabetian C.P., Hancock A.M., Ginghina C., Hong Z., Yearout D., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., Jankovic J., Leverenz J.B., Zhang J. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci. Lett. 2010, 480:78-82.
23. Settembre C., Fraldi A., Rubinsztein D.C., Ballabio A. Lysosomal storage diseases as disorders of autophagy. Autophagy 2008, 4:113-114.
24. Schöndorf D.C., Aureli M., McAllister F.E., Hindley C.J., Mayer F., Schmid B., Sardi S.P., Valsecchi M., Hoffmann S., Schwarz L.K., Hedrich U., Berg D., Shihabuddin L.S., Hu J., Pruszak J., Gygi S.P., Sonnino S., Gasser T., Deleidi M. iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat. Commun. 2014, 5:4028.
25. Shachar T., Lo Bianco C., Recchia A., Wiessner C., Raas-Rothschild A., Futerman A.H. Lysosomal storage disorders and parkinson's disease: gaucher disease and beyond. Mov. Disord. 2011, 26:1593-1604.
26. Sidransky E., Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol. 2012, 11:986-998.